VIMTALABS638.50

Vimta Labs Limited

· Pharma & Health
₹ CrorePeersSUVENTAKEMcap ₹1,416 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
2Y
CAGR
Revenue+0.0+6.9
EBITDA-8.6+4.0
Net Income-14.9-0.4
Total Assets+10.4+14.1
Total Equity+13.5+16.9
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY24 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.